Guilford Gains Rights To Gliatech ADHD Drug Perceptin As Part Of Merger
Guilford Pharmaceuticals has gained rights to Gliatech's adult attention deficit hyperactivity disorder agent Perceptin as part of a merger agreement announced by the companies May 30.
You may also be interested in...
Companies terminate merger agreement following FDA's Aug. 23 inspection report finding inconsistencies in Gliatech's study data for the anti-adhesion gel product Adcon-L. Guilford said Aug. 28 that "in light of Gliatech's need to focus on certain of its ongoing regulatory and product development matters," the parties mutually agreed to end the proposed merger. The $207 mil. merger was announced May 30 (1"The Pink Sheet" June 5, p. 17)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011